We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

31 hedge funds and large institutions have $15.7M invested in Rein Therapeutics in 2017 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

63% more funds holding

Funds holding: 19 → 31 (+12)

1.69% less ownership

Funds ownership: 2.09% → 0.4% (-1.7%)

24% less capital invested

Capital invested by funds: $20.7M → $15.7M (-$5.03M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
31
Holders Change
+12
Holders Change %
+63.16%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
1
Reduced
4
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$594K
3
Northern Trust
Northern Trust
Illinois
+$239K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$218K
5
State Street
State Street
Massachusetts
+$215K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$8.25M
2
NC
Nexthera Capital
New York
-$1.27M
3
Millennium Management
Millennium Management
New York
-$1.07M
4
MIM
Monashee Investment Management
Massachusetts
-$836K
5
HCM
Highbridge Capital Management
New York
-$562K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$3.34M -$8.28K -33 -0.3%
BlackRock
2
BlackRock
New York
$3.16M +$2.96M +11,820 New
CS
3
Candriam SCA
Luxembourg
$2.01M – – –
SFM
4
Sphera Funds Management
Israel
$1.67M – – –
ECM
5
Endurant Capital Management
California
$928K -$248K -987 -22%
Vanguard Group
6
Vanguard Group
Pennsylvania
$767K +$594K +2,367 +473%
Norges Bank
7
Norges Bank
Norway
$669K – – –
Millennium Management
8
Millennium Management
New York
$494K -$1.07M -4,257 -70%
LCM
9
Laurion Capital Management
New York
$401K – – –
MCM
10
Masters Capital Management
Georgia
$401K – – –
Northern Trust
11
Northern Trust
Illinois
$254K +$239K +951 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$233K +$218K +871 New
State Street
13
State Street
Massachusetts
$229K +$215K +859 New
Citigroup
14
Citigroup
New York
$222K +$208K +828 New
Charles Schwab
15
Charles Schwab
California
$165K +$154K +615 New
Bank of America
16
Bank of America
North Carolina
$136K -$8.25M -32,899 -98%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$135K +$126K +501 New
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$110K +$103K +410 New
Morgan Stanley
19
Morgan Stanley
New York
$86K +$80.8K +322 New
TA
20
Teachers Advisors
New York
$79K +$74K +295 New
Deutsche Bank
21
Deutsche Bank
Germany
$60K +$57.4K +229 New
AIG
22
American International Group
New York
$39K +$36.4K +145 New
NFA
23
Nationwide Fund Advisors
Ohio
$34K +$31.9K +127 New
SO
24
STRS Ohio
Ohio
$20K +$18.8K +75 New
UBS Group
25
UBS Group
Switzerland
$16K +$14.5K +58 New
1
2

RNTX Hedge Fund Activity: Q3 2017 in Review

31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2017, worth a combined $15.7M — down 24% from $20.7M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new RNTX positions and 9 closed out — a net gain of 12 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $2.96M. The largest seller was Bank of America, cutting an estimated $8.25M.

  • 31 institutional investors held Rein Therapeutics (RNTX) as of Q3 2017, up from 19 in Q2 2017.
  • Funds reported $15.7M of Rein Therapeutics stock for Q3 2017, down 24% quarter-over-quarter.
  • 21 funds opened new Rein Therapeutics positions in Q3 2017 and 9 closed out, a net change of +12 holders.
  • The largest Rein Therapeutics buyer in Q3 2017 was BlackRock, an estimated $2.96M added.
  • The largest Rein Therapeutics seller in Q3 2017 was Bank of America, an estimated $8.25M sold.

Based on aggregated 13F filings for Q3 2017.